Skip to main content
. Author manuscript; available in PMC: 2013 Aug 20.
Published in final edited form as: Chem Res Toxicol. 2012 Jul 26;25(8):1752–1761. doi: 10.1021/tx300215g

Figure 2.

Figure 2

His-67 of human albumin forms concatenated-[2]-o-hydroxybenzyl adduct upon treatment with CBDP. MALDI MS/MS spectrum of parent ion (MH) at m/z 1229.6 corresponds to the peptide SLH*TLFGDK, where the asterisk indicates the position of concatenated-[2]-o-hydroxybenzyl adduct. The peak at m/z 1123.5 is consistent with the neutral loss of o-hydroxybenzyl moiety (MH-106). The peak at m/z 1017.5 is consistent with the neutral loss of concatenated-[2]-o-hydroxybenzyl moiety (MH-212).